{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:13Z","timestamp":1790889913600,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,14]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Targeting ROR1 downregulates NF-\u03baB p65 expression and sensitizes MCL cells to BCR- or Bcl-2\u2013targeted drugs. Inhibition of BCR signaling by BTK-specific inhibitors such as ibrutinib impairs ROR1 levels and consecutively ROR1-targeted therapies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017010215","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T01:45:28Z","timestamp":1510278328000},"page":"2257-2268","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma"],"prefix":"10.1182","volume":"1","author":[{"given":"Hanna","family":"Karvonen","sequence":"first","affiliation":[{"name":"BioMediTech Institute and"},{"name":"Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chiron","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers, INSERM, Centre National de la Recherche Scientifique, Universit\u00e9 de Nantes, Centre Hospitalier Universitaire de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelmiina","family":"Niininen","sequence":"additional","affiliation":[{"name":"BioMediTech Institute and"},{"name":"Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ek","sequence":"additional","affiliation":[{"name":"Department of Immunotechnology, Faculty of Engineering, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Institute of Clinical Sciences, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Moradi","sequence":"additional","affiliation":[{"name":"BioMediTech Institute and"},{"name":"Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Nykter","sequence":"additional","affiliation":[{"name":"BioMediTech Institute and"},{"name":"Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland; and"},{"name":"Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Murum\u00e4gi","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"BioMediTech Institute and"},{"name":"Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"issue":"1","key":"2019111616264346400_B1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"issue":"45","key":"2019111616264346400_B2","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111616264346400_B3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2019111616264346400_B4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111616264346400_B5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"9","key":"2019111616264346400_B6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"11","key":"2019111616264346400_B7","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"issue":"21","key":"2019111616264346400_B8","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V122.21.1789.1789","article-title":"The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients","volume":"122","author":"Seymour","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2019111616264346400_B9","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"36","key":"2019111616264346400_B10","doi-asserted-by":"crossref","first-page":"26181","DOI":"10.1016\/S0021-9258(18)35733-8","article-title":"A novel family of cell surface receptors with tyrosine kinase-like domain","volume":"267","author":"Masiakowski","year":"1992","journal-title":"J Biol Chem"},{"issue":"11","key":"2019111616264346400_B11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tcb.2008.08.006","article-title":"Ror receptor tyrosine kinases: orphans no more","volume":"18","author":"Green","year":"2008","journal-title":"Trends Cell Biol"},{"issue":"2","key":"2019111616264346400_B12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/BJ20131174","article-title":"A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties","volume":"457","author":"Murphy","year":"2014","journal-title":"Biochem J"},{"issue":"4","key":"2019111616264346400_B13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1042\/BST20130104","article-title":"Receptor tyrosine kinases with intracellular pseudokinase domains","volume":"41","author":"Mendrola","year":"2013","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"2019111616264346400_B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2443.1999.00234.x","article-title":"Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system","volume":"4","author":"Oishi","year":"1999","journal-title":"Genes Cells"},{"issue":"7","key":"2019111616264346400_B15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein Cell"},{"issue":"9","key":"2019111616264346400_B16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8090079","article-title":"Wnt5a signaling in cancer","volume":"8","author":"Asem","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2019111616264346400_B17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3892\/ijmm_00000190","article-title":"Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades","volume":"23","author":"Katoh","year":"2009","journal-title":"Int J Mol Med"},{"issue":"9","key":"2019111616264346400_B18","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.4049\/jimmunol.1302817","article-title":"Wnt5a-Rac1-NF-\u03baB homeostatic circuitry sustains innate immune functions in macrophages","volume":"192","author":"Naskar","year":"2014","journal-title":"J Immunol"},{"issue":"2","key":"2019111616264346400_B19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","author":"Yu","year":"2016","journal-title":"J Clin Invest"},{"issue":"25","key":"2019111616264346400_B20","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111616264346400_B21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","article-title":"Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia","volume":"22","author":"Bicocca","year":"2012","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111616264346400_B22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2141.2010.08362.x","article-title":"Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells","volume":"151","author":"Choudhury","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111616264346400_B23","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2011.362","article-title":"Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells","volume":"26","author":"Daneshmanesh","year":"2012","journal-title":"Leukemia"},{"issue":"suppl","key":"2019111616264346400_B24","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.clml.2015.02.010","article-title":"Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1","volume":"15","author":"Choi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2019111616264346400_B25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2019111616264346400_B26","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1186\/s12885-016-2844-6","article-title":"The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma","volume":"16","author":"Hanf","year":"2016","journal-title":"BMC Cancer"},{"issue":"20","key":"2019111616264346400_B27","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111616264346400_B28","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"38","key":"2019111616264346400_B29","doi-asserted-by":"crossref","first-page":"15939","DOI":"10.1074\/jbc.M117.785709","article-title":"The Ror1 receptor tyrosine kinase plays a critical role in regulating satellite cell proliferation during regeneration of injured muscle","volume":"292","author":"Kamizaki","year":"2017","journal-title":"J Biol Chem"},{"issue":"3","key":"2019111616264346400_B30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/mabs.19870","article-title":"Targeting malignant B cells with an immunotoxin against ROR1","volume":"4","author":"Baskar","year":"2012","journal-title":"MAbs"},{"issue":"2","key":"2019111616264346400_B31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.CCR-15-0154","article-title":"Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia","volume":"22","author":"Janovska","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111616264346400_B32","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"issue":"48","key":"2019111616264346400_B33","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/onc.2016.155","article-title":"FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"2019111616264346400_B34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.948","article-title":"ROR1 expression is not a unique marker of CLL","volume":"29","author":"Barna","year":"2011","journal-title":"Hematol Oncol"},{"issue":"2","key":"2019111616264346400_B35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2013.01.018","article-title":"ABT-199: taking dead aim at BCL-2","volume":"23","author":"Davids","year":"2013","journal-title":"Cancer Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/24\/2257\/879069\/advances010215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/24\/2257\/879069\/advances010215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T23:38:28Z","timestamp":1659829108000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/24\/2257\/16217\/Crosstalk-between-ROR1-and-BCR-pathways-defines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":35,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017010215","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}